Your search for Warfarin returned 15 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Uncategorized remove

Your search for Warfarin returned 15 results

Sort Results:

Relevant Recent
Uncategorized

FDA: Pradaxa vs. Warfarin Study Results Announced

The FDA announced the results of a new study on Medicare patients comparing Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim Pharmaceuticals) vs. warfarin for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death.
Uncategorized

FDA Updates on Bleeding Risk of Pradaxa

The FDA's recommendations regarding Pradaxa remain unchanged following the November 2012 Mini-Sentinel evaluations. Findings showed that bleeding rates associated with Pradaxa use during the period did not appear to be higher than those associated with warfarin.
Uncategorized

False PT/INR Results May Appear for Some Patients

Alere has issued a voluntary correction to users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with the system.
Uncategorized

Jantoven 3mg tablets recalled due to mislabeling

Upsher-Smith Laboratories announced a nationwide voluntary recall of Jantoven (warfarin sodium) 3mg tablets with an expiration date of September 2012, Lot #284081NDC #0832-1214-00.
Uncategorized

Pradaxa Label Updated with New Contraindication

Boehringer Ingelheim announced that the prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.
Uncategorized

Upsher-Smith expands nationwide product recall

Upsher-Smith Laboratories is voluntarily expanding its previously announced recall of Jantoven (warfarin sodium) 3mg tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010.
Uncategorized

Celgene distributes a letter for Innohep

Celgene has issued a Dear Healthcare Professional letter describing a controlled clinical study suggesting that Innohep injection (tinzaparin sodium) may increase the risk for death, compared to unfractionated heparin (UFH) when used to treat elderly patients with renal insufficiency.